Avastin | Bevacizumab (download only)

Regular price $0.00

Avastin (bevacizumab) is an antibody drug that binds to and neutralises a protein called VEGF-A.

It is effective as first-line treatment for metastatic bowel cancer and is used in combination with chemotherapy.

The drug is also approved as part of second line treatment in combination with chemotherapy. 

Is Avastin available on the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?

    • Avastin is PBS-subsidised as a treatment option in combination with first-line chemotherapy (i.e. first-line treatment option), of a patient with previously untreated metastatic bowel cancer.
    • Avastin is PBS-subsidised as a treatment option in combination with second-line chemotherapy, of a patient with RAS wild-type metastatic bowel cancer, who have been previously treated with PBS-subsidised first-line anti-EGFR antibodies.

      Download the Consumer Medicine Information (CMI) for Avastin.